NATCO Pharma (NATCOPHARM) announced its Q2FY26 results, reporting a consolidated total revenue of ₹1,463.0 Crore, compared to ₹1,434.9 crore in Q2FY25. Profit after tax stood at ₹517.9 Crore. The Board declared an interim dividend of ₹1.5 per share. The company’s Crop Health Sciences business will be demerged into a separate entity. NATCO also completed the acquisition of 35.75% equity in Adcock Ingram Holdings Limited, South Africa.
Financial Performance
NATCO Pharma reported a consolidated total revenue of ₹1,463.0 Crore for the quarter ended September 30, 2025 (Q2FY26), as compared to ₹1,434.9 crore for the same quarter in the previous year. EBITDA, including other income, stood at ₹679.2 Crore, with margins at 46.4%. The net profit for the period, on a consolidated basis, was ₹517.9 Crore.
Segment Revenue Breakdown
Segment-wise revenue for Q2FY26 (in INR Crore):
- Active Pharmaceutical Ingredients (API): 53.9
- Domestic Formulations: 105.4
- Formulations export (incl. profit share and subs): 1,147.0
- Crop Health Sciences (CHS): 52.4
- Other operating and non-operating income: 104.3
Dividend Announcement
The Board of Directors has declared an interim dividend of ₹1.5 per equity share of ₹2 each during Q2FY26.
Strategic Developments
Further to the earlier announcement, the company is proceeding with the demerger of its Crop Health Sciences (CHS) business into a separate legal entity.
NATCO completed the acquisition of 51,643,319 shares of Adcock Ingram Holdings Limited (“Adcock”), South Africa, representing 35.75% of its equity share capital, for a total purchase consideration of ZAR 3,873 million (USD 225 million).
Source: BSE
